Related Experiment Videos
[Combination therapy against vancomycin-resistant enterococci]
1Department of Urology, Okayama University Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 18, 2001
Summary
Vancomycin-resistant enterococci infections have limited treatment options. The combination of ampicillin and arbekacin shows promise for treating these difficult infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Context:
- Limited therapeutic options exist for vancomycin-resistant enterococci (VRE) infections.
- Optimal treatment for serious enterococcal infections involves synergistic combinations of cell wall-active agents and aminoglycosides.
- Increasing aminoglycoside resistance in enterococci compromises traditional therapeutic strategies.
Purpose:
- To evaluate the efficacy of arbekacin, a novel semi-synthetic aminoglycoside, against resistant enterococci.
- To assess the synergistic activity of ampicillin combined with arbekacin against vancomycin-resistant enterococci.
Summary:
- Arbekacin exhibits potent activity against bacteria producing aminoglycoside-modifying enzymes, including those found in resistant enterococci.
- The combination of ampicillin and arbekacin demonstrated significant inhibitory activity against vancomycin-resistant enterococci in recent studies.
- This combination may offer a viable therapeutic option for treating challenging enterococcal infections.
Impact:
- Provides a potential new therapeutic strategy for infections caused by multidrug-resistant enterococci.
- Addresses the critical need for effective treatments against vancomycin-resistant enterococci.
- May help mitigate the impact of antibiotic resistance on patient outcomes.